Related Experiment Videos
A novel approach to tumor suppression using microencapsulated engineered J558/TNF-alpha cells
Siguo Hao1, Liping Su, Xulin Guo
1Department of Oncology, Research Unit, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon, Saskatchewan S7N 4H4, Canada.
Experimental Oncology
|April 7, 2005
Summary
Microencapsulation of engineered cancer cells secreting tumor necrosis factor-alpha (TNF-alpha) effectively reduced tumor growth in mice. This immunoisolation technology offers a promising new avenue for cancer treatment.
Area of Science:
- Biotechnology
- Oncology
- Cell Therapy
Background:
- Immunoisolation using microencapsulated nonautologous cells presents a novel cancer treatment strategy.
- Engineering cells to secrete therapeutic agents is a key aspect of advanced cancer therapies.
Purpose of the Study:
- To investigate the efficacy of microencapsulated engineered cells secreting tumor necrosis factor-alpha (TNF-alpha) in inhibiting tumor growth in vivo.
- To evaluate the potential of immunoisolation technology as an alternative cancer treatment approach.
Main Methods:
- Constructed J558/TNF-alpha cell line secreting functional TNF-alpha.
- Encapsulated engineered cells into microcapsules for in vivo implantation.
- Intratumorally implanted microencapsulates into mice bearing human breast cancer (MCF-7).
Main Results:
- Microencapsulates released functional TNF-alpha, demonstrating in vitro cytotoxicity.
- Intratumoral implantation led to significant tumor cell apoptosis and necrosis.
- Observed significant tumor regression and slower tumor growth compared to control groups.
Conclusions:
- Microencapsulation of recombinant tumor cells secreting cytokines is a viable alternative cancer treatment.
- This approach shows promise for inducing tumor regression and controlling tumor progression.